These data demonstrate that TVB inhibitors have anti-tumor activity in CRC and suggest that the level of FASN expression and the activity of oncogenic pathways such as Akt and AMPK may determine the responsiveness of CRC to FASN inhibition. The gene discussed is AKT1; the disease is neoplasm.